Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Ado-trastuzumab emtansine approved for advanced breast cancer.

Traynor K.

Am J Health Syst Pharm. 2013 Apr 1;70(7):562. doi: 10.2146/news130023. No abstract available. Erratum in: Am J Health Syst Pharm. 2013 May 15;70(10):840.

PMID:
23515502
2.

Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2013 Sep 16;55(1425):75-6. No abstract available.

PMID:
24662957
3.

Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2013 Sep 16;55(1424):75-6. No abstract available.

PMID:
24043217
4.

Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.

Patel KC, Hageman K, Cooper MR.

Am J Health Syst Pharm. 2014 Apr 1;71(7):537-48. doi: 10.2146/ajhp130342. Review.

PMID:
24644113
5.

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

Baron JM, Boster BL, Barnett CM.

J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27. Review.

PMID:
24682654
6.

FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 Sep 1;20(17):4436-41. doi: 10.1158/1078-0432.CCR-14-0012. Epub 2014 May 30.

7.

Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.

Cho WC, Roukos DH.

Expert Rev Anticancer Ther. 2013 Jan;13(1):5-8. doi: 10.1586/era.12.152. No abstract available.

PMID:
23259420
8.

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA.

Cancer J. 2015 Sep-Oct;21(5):357-64. doi: 10.1097/PPO.0000000000000144.

PMID:
26389758
9.

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.

Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, Shimizu C, Hara F, Takabatake D, Hattori M, Asakawa T, Fujiwara Y.

Jpn J Clin Oncol. 2015 Jan;45(1):12-8. doi: 10.1093/jjco/hyu160. Epub 2014 Oct 20.

PMID:
25332421
10.
11.

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

Krop I, Winer EP.

Clin Cancer Res. 2014 Jan 1;20(1):15-20. doi: 10.1158/1078-0432.CCR-13-0541. Epub 2013 Oct 17.

12.

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN, Modi S.

Cancer. 2012 Dec 1;118(23):5733-40. doi: 10.1002/cncr.27622. Epub 2012 May 30.

13.

Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.

Bourdeanu L, Luu T.

Clin J Oncol Nurs. 2013 Oct;17(5):E58-62. doi: 10.1188/13.CJON.E58-E62.

PMID:
24080060
14.

Trastuzumab emtansine: first global approval.

Ballantyne A, Dhillon S.

Drugs. 2013 May;73(7):755-65. doi: 10.1007/s40265-013-0050-2. Review.

PMID:
23620199
15.

Desensitization to chemotherapeutic agents.

Lieberman P, Castells M.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):116-7. doi: 10.1016/j.jaip.2013.08.013. No abstract available.

PMID:
24565784
16.

From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.

Lianos GD, Roukos DH.

Future Oncol. 2014 Feb;10(2):145-8. doi: 10.2217/fon.13.252. No abstract available.

17.

Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.

Haddley K.

Drugs Today (Barc). 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. Review.

PMID:
24308017
18.

Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.

Van den Mooter T, Teuwen LA, Rutten A, Dirix L.

Expert Opin Biol Ther. 2015 May;15(5):749-60. doi: 10.1517/14712598.2015.1036026. Review.

PMID:
25865453
19.

Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.

Barginear MF, John V, Budman DR.

Mol Med. 2013 Jan 22;18:1473-9. doi: 10.2119/molmed.2012.00302.

20.

Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.

Muzaffar M, Jia J, Liles D, Naveed M, Kumari A.

Am J Ther. 2016 Mar-Apr;23(2):e572-4. doi: 10.1097/MJT.0000000000000179.

PMID:
25756468

Supplemental Content

Support Center